The tussle had centred on the development of mRNA jab technology, which was at the forefront of the fight against Covid-19.

GlaxoSmithKline plc (UK) (($GB:GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) is ...

In a report released today, Justin Smith from Bernstein maintained a Buy rating on GlaxoSmithKline, with a price target of £21.70. The company’s shares closed today at p1,373.00. Take advantage of ...

Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...

GSK will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology and ...

UK-based big pharma GlaxoSmithKline (GSK) has released its Q2 2025 results, which highlight the varying successes of its ...

Indian drugmaker GlaxoSmithKline Pharma reported its first quarterly revenue decline in more than two years on Friday, ...

U.S. Senator Maggie Hassan said on Friday she is launching an investigation into British pharmaceutical giant GlaxoSmithKline's decision to discontinue a widely used asthma inhaler for children.

Beats Q2 Earnings & Sales Estimates, Ups 2024 Guidance GSK reported core earnings of $1.09 per American depositary share (ADS) for second-quarter 2024, beating the Zacks Consensus Estimate of $1.00.

Glaxo (GSK) rejects an offer from Unilever to acquire its consumer business worth 50 billion pounds ($68 billion). However, Unilever is likely to pursue the acquisition of the business.

GSK expects both core operating profit and core EPS to grow in the range of 6-8% including the impact of the share buyback program. R&D is expected to increase at a rate similar to sales growth.

GlaxoSmithKline GSK, +1.18% (GSK), Europe's largest drugmaker, said second-quarter net income slipped to 1.29 billion pounds ($2.6 billion) from 1.33 billion pounds, with revenue rising to 5.87 ...